Lucio Amitrano

Lucio Amitrano

Auto-generated profile, based on publicly available information

Lucio Amitrano

Gastroenterology Unit, A. Cardarelli Hospital, Naples, Italy

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2004 in Journal of Hepatology
Verified
Journal Article
Closed access
LALucio Amitrano
Lucio Amitrano
MGMaria Anna Guardascione
Maria Anna Guardascione
VBVincenzo Brancaccio
Vincenzo Brancaccio
MMMaurizio Margaglione
Maurizio Margaglione
FMFrancesco Manguso
Francesco Manguso
ABAntonio Balzano
Antonio Balzano

27 March 2002 in Seminars in Liver Disease
Verified
Journal Article
Closed access
LALucio Amitrano
Lucio Amitrano
MGMaria A. Guardascione
Maria A. Guardascione
VBVincenzo Brancaccio
Vincenzo Brancaccio
ABAntonio Balzano
Antonio Balzano
The liver plays a central role in the clotting process, and acute and chronic liver diseases are invariably associated with coagulation disorders due to multiple causes: decreased synthesis of clotting and inhibitor factors, decreased clearance of activated factors, quantitative and qualitative platelet defects, hyperfibrinolysis, and accelerated intravascular coagulation. The bleeding tendency accounts for increased risk of morbidity and mortality in patients with liver disease undergoing diagnostic or therapeutic invasive procedures. Peculiar coagulation disorders are prevalent in patients with acute fatty liver of pregnancy or undergoing liver transplantation. Emerging evidence shows that sepsis further impairs hemostasis in patients with liver cirrhosis bleeding from esophageal varices. Thrombotic events, even if rare in cirrhotic patients, occur mainly in the portal and mesenteric veins. The therapeutic approach to coagulative disorders is also discussed.

1 July 2010 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
LALucio Amitrano
Lucio Amitrano
MGMaria Anna Guardascione
Maria Anna Guardascione
AMAntonella Menchise
Antonella Menchise
RMRossana Martino
Rossana Martino
Mariano ScaglioneMariano Scaglione
Mariano Scaglione
ABAntonio Balzano
Antonio Balzano
Background Treatment of portal vein thrombosis (PVT) in patients with liver cirrhosis is not well established. Aim We intended to assess the safety and efficacy of low molecular weight heparin (LMWH) to treat PVT in cirrhotic patients. Study All 39 patients diagnosed with non-neoplastic PVT and cirrhosis from June 2005 to December 2006 were evaluated for anticoagulation therapy (AT). PVT was occludent in 15.4%, partial in 64.1%, and portal cavernoma presented in 20.5%. Twenty-eight patients received 200 U/kg/d of enoxaparin for at least 6 months. In 39.3% of patients PVT was an occasional finding, in 10.7% presented with acute abdominal pain, in 50% with bleeding from gastroesophageal varices. In this last group LMWH was started after endoscopic eradication of varices by band ligation. Results Complete recanalization of portal vein occurred in 33.3%, partial recanalization in 50% and no response in 16.7% of patients. Further 12 patients who continued AT obtained complete recanalization at a median time of 11 months (range 7 to 17 mo). Overall, a complete response was obtained in 75% of patients. No significant side effects, particularly bleeding complications, were observed during the treatment. Conclusions LMWH demonstrated safe and effective in the treatment of PVT in patients with liver cirrhosis.

1 February 2000 in Hepatology
Verified
Journal Article
Open access
PDF file
LALucio Amitrano
Lucio Amitrano
VBVincenzo Brancaccio
Vincenzo Brancaccio
MGMaria Anna Guardascione
Maria Anna Guardascione
MMMaurizio Margaglione
Maurizio Margaglione
LILuigi Iannaccone
Luigi Iannaccone
ABAntonio Balzano
Antonio Balzano
The prevalence and pathogenesis of portal vein thrombosis (PVT) in patients with cirrhosis without hepatocellular carcinoma are not clearly defined. The role of thrombophilic genetic factors is well established in other venous thrombotic diseases, as well as in noncirrhotic portal thrombosis. Recently, new, inherited thrombophilic disorders (factor V Leiden [FVL], mutation G20210A of prothrombin [PTHR A20210], and mutation TT677 of methylenetetrahydrofolate reductase [MTHFR C677→T]) have been identified and associated with increased risk of venous thrombosis. The aim of our study was to investigate the role of these thrombophilic disorders in the pathogenesis of PVT in cirrhotic patients. Twenty-three cirrhotic patients with PVT and 40 cirrhotics without PVT were included. A group of 184 patients with deep vein thrombosis (DVT) and 431 healthy persons served as controls. The FVL, PTHR A20210, and MTHFR C677→T genotypes were identified by a polymerase chain reaction and restriction analysis. The frequencies of FVL, PTHR A20210mutation, and homozygous MTHFR C677→T were 13%, 34.8%, and 43.5% in cirrhotic patients with PVT and 7.5%, 2.5%, and 5% in cirrhotic patients without PVT, respectively. Five patients in the former group had associated defects. A thrombophilic genotype was detected in 69.5% of the patients with PVT. Identification of this high-risk group may have implications in patients who are candidates for major surgery or liver transplantation, and may influence the duration of oral anticoagulation.

1 December 2012 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
LALucio Amitrano
Lucio Amitrano
MGMaria Anna Guardascione
Maria Anna Guardascione
FMFrancesco Manguso
Francesco Manguso
RBRaffaele Bennato
Raffaele Bennato
ABAntonio Bove
Antonio Bove
ERElisabetta Riccio
Elisabetta Riccio
The American Journal of Gastroenterology is published by Nature Publishing Group (NPG) on behalf of the American College of Gastroenterology (ACG). Ranked the #1 clinical journal covering gastroenterology and hepatology*, The American Journal of Gastroenterology (AJG) provides practical and professional support for clinicians dealing with the gastroenterological disorders seen most often in patients. Published with practicing clinicians in mind, the journal aims to be easily accessible, organizing its content by topic, both online and in print. www.amjgastro.com, *2007 Journal Citation Report (Thomson Reuters, 2008)

1 June 2005 in Journal of Hepatology
Verified
Journal Article
Closed access
LALucio Amitrano
Lucio Amitrano
MGMaria Anna Guardascione
Maria Anna Guardascione
RBRaffaele Bennato
Raffaele Bennato
FMFrancesco Manguso
Francesco Manguso
ABAntonio Balzano
Antonio Balzano